Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$24.04M+370.65%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Scott Hutton
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 334
- Beta
- 0.55
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -6.53
Financials
Revenue
$24.04M+370.7%Net Income
$-8.03MEBITDA
$-4.63MFree Cash Flow
$-7.64MEPS (diluted)
$-0.75Shares Outstanding (diluted)
10.66M+715.9%Operating Expenses
$25.49MCash & Debt
$28.41MRevenue by Segment (annual)
$88.50MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $88.50M | $-35.27M | $-4.67 |
| 2024 | $71.32M | $-42.93M | $-6.62 |
| 2023 | $49.09M | $-52.15M | $-12.70 |
| 2022 | $38.21M | $-65.45M | $-31.09 |
| 2021 | $54.51M | $-43.16M | $-31.54 |
| 2020 | $45.56M | $-31.35M | $-23.61 |
| 2019 | $24.55M | $-30.73M | $-2410.66 |
| 2018 | $20.43M | $-26.17M | $-19.72 |
Valuation
BDSXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
0-100.00%Social Signal Score
Mentions (21)
- Newsbusinesswire.com·1d ago·Negative
BDSX Investors Have Opportunity to Join Biodesix, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $BDSX--BDSX Investors Have Opportunity to Join Biodesix, Inc. Fraud Investigation with SBS Law.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Biodesix, Inc. (BDSX) Presents at 2026 UBS Global Healthcare Conference Transcript Biodesix, Inc. (BDSX) Presents at 2026 UBS Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·16d ago·Positive
Champions Oncology vs. Biodesix: Which Oncology Stock Is a Better Buy? CSBR and BDSX ride on distinct oncology growth drivers, but which stock looks more compelling amid contrasting performance and valuations? Let's dive in.
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Biodesix, Inc. (BDSX) Q3 2026 Earnings Call Transcript Biodesix, Inc. (BDSX) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·17d ago·Negative
Biodesix, Inc. (BDSX) Reports Q3 Loss, Lags Revenue Estimates Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to a loss of $1.16 per share a year ago.
View source ↗ - Newsmarketbeat.com·17d ago·Negative
What Biodesix (BDSX) Said on Its Q3 Earnings Call Biodesix NASDAQ: BDSX reported 10% revenue growth for the third quarter of 2026 but said results fell short of its expectations as a smaller-than-planned sales force, seasonal patterns in primary care and delayed customer projects weighed on performance.
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Biodesix to Participate in Upcoming Investor Conferences LOUISVILLE, Colo., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present at two upcoming investor conferences:
View source ↗ - Newszacks.com·24d ago·Positive
All You Need to Know About Biodesix (BDSX) Rating Upgrade to Buy Biodesix (BDSX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newszacks.com·24d ago·Neutral
Will Biodesix, Inc. (BDSX) Report Negative Earnings Next Week? What You Should Know Biodesix (BDSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026 LOUISVILLE, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30, 2026 after the close of trading on Thursday, November 5. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Ea…
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practices New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practices
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessment
View source ↗ - Newsglobenewswire.com·40d ago·Negative
Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026 New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencing
View source ↗ - Newszacks.com·55d ago·Neutral
Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.
View source ↗ - Newsglobenewswire.com·59d ago·Neutral
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise
View source ↗ - Newsglobenewswire.com·69d ago·Neutral
Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules
View source ↗ - Newsglobenewswire.com·80d ago·Neutral
Biodesix to Participate in Upcoming Investor Conferences LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming investor conferences:
View source ↗ - Newszacks.com·83d ago·Positive
What Makes Biodesix, Inc. (BDSX) a Strong Momentum Stock: Buy Now? Does Biodesix, Inc. (BDSX) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newszacks.com·83d ago·Neutral
Wall Street Analysts See a 26.72% Upside in Biodesix (BDSX): Can the Stock Really Move This High? The consensus price target hints at a 26.7% upside potential for Biodesix (BDSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newsmarketbeat.com·102d ago·Neutral
Biodesix Sees Nodify Growth, Reaffirms Revenue Outlook at Canaccord Conference Biodesix NASDAQ: BDSX said its commercial expansion, broader primary care outreach and recently published clinical data supporting use of its Nodify CDT test in smaller lung nodules are among the principal drivers of its growth strategy.
View source ↗ - Newszacks.com·103d ago·Positive
Biodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue? Biodesix (BDSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-0.70 per share
Typical surprise +24.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.75 vs $-0.75miss
- Wed, Aug 5$-0.71 vs $-0.90beat
- Mon, May 4$-0.81 vs $-1.26beat
- Thu, Feb 26$-0.49 vs $-1.05beat
- Mon, Nov 3$-1.16 vs $-1.60beat
- Thu, Aug 7$-1.60 vs $-1.40miss
Estimates and results for BDSX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BDSX officers and directors.
- Bought
- $5.1m
- Sold
- $118k
8 trades
20 trades
- Schuler Jack Wbought
- Schuler Jack Wbought
- Schuler Jack Wbought
- Schuler Jack Wbought
- Pestano Gary Anthonysold
- O'kane Kieransold
- Cowie Robin Harpersold
- Vazquez Chrissold
72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BDSX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
